Olympus Scope

Olympus Duodenoscope/Endoscope Litigation – Fast Evaluation

Author: Written by Michael Stanisci (MassTortMichael)

Olympus Scope

I'm adding "open item" tags for updates I need to return back to.

1. Snapshot

   1. Olympus duodenoscopes, especially the TJF‑Q180V series, have been linked to infections due to reprocessing challenges and design issues. The FDA cleared safety modifications in 2016 and Olympus later initiated corrective actions and replacements, while pleading guilty in 2018 to failures in adverse‑event reporting tied to duodenoscope infections. [AHA News] [FDA Recall Z-2807-2015] [FDA Recall Z-0379-2022] [Loeb & Loeb]

2. Plaintiff Numerosity

   1. Potential exposure is large. FDA records show 6,109 TJF‑Q180V units were in commerce globally by 2015, with U.S. nationwide distribution and later FDA‑noted 14,447 units implicated in 2021 corrective actions, indicating a broad installed base for ERCP procedures. Epidemiologic numerosity is tied to scope usage volumes and documented outbreaks. SOL will vary by state, with discovery‑rule arguments centered on later FDA and Olympus notices. [FDA Recall Z-2807-2015] [FDA Recall Z-0379-2022] [AHA News]

3. Defendant Viability

   1. Primary defendants include Olympus Corporation, Olympus Corporation of the Americas, and Olympus Medical Systems (subsidiary structure with U.S. distribution through Olympus America). Olympus is a large multinational with capacity signals including prior nine‑figure regulatory settlements and ability to fund device replacements and programs. [FDA Recall Z-2807-2015] [FDA Recall Z-0379-2022] [Loeb & Loeb]

4. Financial Viability

   1. Olympus paid $85 million in criminal fines and forfeitures for failing to file required adverse‑event reports related to duodenoscope infections, alongside mandated compliance reforms. Separate from device issues, Olympus Corporation of the Americas previously resolved federal kickback allegations for more than $600 million, signaling substantial resources and insurance/balance sheet depth. Earnings‑call reserves not publicly compiled here. [Loeb & Loeb] [JDSupra/Polsinelli]

5. Scientific Viability

   1. Primary adverse event: Sepsis

   2. Mechanistic plausibility centers on duodenoscope elevator mechanisms and channels that can trap bioburden, making high‑level disinfection difficult and allowing contamination despite reprocessing. FDA‑acknowledged design and labeling changes, plus enhanced reprocessing protocols and later transitions to next‑generation scopes, support general causation theory for procedure‑linked infections. Causation still requires differential diagnosis, proof of reprocessing adequacy, and device condition. [FDA Recall Z-2807-2015] [AHA News] [FDA Recall Z-0379-2022] [Gastroenterology & Endoscopy News]

6. Time to Resolution

   1. Phase: mature but fragmented. Many individual and institutional cases have resolved or proceeded without a central MDL. Device corrections began in 2015–2016, with additional corrective actions in 2021–2022 and programs transitioning users to newer models. Resolution timelines for new filings will depend on venue and expert posture, with a 1–3 year window typical for individual hospital/provider cases if liability and causation are strong. [AHA News] [FDA Recall Z-2807-2015] [FDA Recall Z-0379-2022]

7. Venue of MDL (if applicable)

   1. Open item. No current federal MDL specific to Olympus duodenoscope infections is identified in the sources reviewed here. Many cases historically proceeded in state and federal courts individually or in coordinated proceedings. Verify in the future the current JPML status and any state JCCP‑type consolidations. [Open item for JPML docket verification]

8. Bellwether Results

   1. Open item. Public reporting in the sourced materials does not compile specific bellwether verdicts for Olympus duodenoscope infection cases. Some matters appear to have resolved confidentially or via institutional settlements. This limits direct benchmarking to settlement value. [Open item]

9. Daubert and Frye Analysis

   1. Expert issues likely focus on infection control, device design, microbiology of biofilm formation, and adequacy of reprocessing protocols. The FDA‑mandated modifications and corrective actions strengthen admissibility arguments on general causation. Specific causation will hinge on hospital logs, reprocessing compliance, culture results, and scope inspection/maintenance records. No specific Daubert/Frye rulings surfaced in the reviewed sources. [FDA Recall Z-2807-2015] [FDA Recall Z-0379-2022] [AHA News]

10. State of Litigation

    1. Key milestones: 2015–2016 FDA‑cleared safety modifications and recall to retrofit the TJF‑Q180V; subsequent updates directing increased inspections, maintenance intervals, and transition to newer‑generation duodenoscopes, including no‑cost replacements to TJF‑Q190V referenced in 2022 update language. 2018 Olympus criminal plea regarding MDR failures tied to duodenoscope infections with compliance obligations. Continued FDA tracking of corrective actions in 2021–2022. [AHA News] [FDA Recall Z-2807-2015] [FDA Recall Z-0379-2022] [Loeb & Loeb]

11. Business View

    1. Risk level (1–10): 6 – Liability theories are supported by FDA‑recognized design and reprocessing issues, but specific causation is case‑intensive and hospital practices are confounders.

    2. PACV range: $50,000 – $500,000+ per strong case, depending on severity, proof of contamination path, cultures, and damages; outliers possible for severe injury or death with strong proof sets. These are estimates only, and individual results will vary.

    3. PPN signal: medium – Cases exist, but documentation and chain‑of‑causation burdens are high. Hospital co‑defendants and comparative fault can complicate recovery.

    4. TCPCA guidance: In a mature but non‑MDL environment, acceptable CPCA should be conservative and tied to early records triage. Raise CPCA only when you have culture matches, reprocessing logs, and scope maintenance/inspection records that align with FDA‑flagged defects.

    5. Suggested posture: watch/targeted entry – Prioritize highly documented infections temporally linked to ERCP with scope model identification, reprocessing compliance proof, and culture data. Broad intake without documentation discipline is not advised.

Acronyms

• FDA: U.S. Food and Drug Administration

• ERCP: Endoscopic Retrograde Cholangiopancreatography

• MDR: Medical Device Report (adverse event report to FDA)

• DOJ: U.S. Department of Justice

• MDL: Multidistrict Litigation

• JPML: Judicial Panel on Multidistrict Litigation

• JCCP: Judicial Council Coordinated Proceeding (California)

• SOL: Statute of Limitations

• BBW: Boxed Warning

• Daubert: Federal standard for expert evidence admissibility

• Frye: General‑acceptance expert evidence standard in some states

• PACV: Probable Average Case Value

• PPN: Probability of Payout Now

• TCPCA: Target Cost Per Case Acquired

• CMO/PTO: Case Management Order / Pretrial Order

• UDI: Unique Device Identifier

• 510(k): FDA premarket notification pathway

• AE: Adverse Event

• HLD: High‑Level Disinfection

• Q180V/Q190V: Olympus duodenoscope model families

• TPLC: Total Product Life Cycle

Contact Michael

• If you are a potential claimant, I can help connect you with the right law firm.

• If you are an attorney, I can help end-to-end: improve operations, add the right tech, and grow with new claimant acquisition.

• Website: https://www.masstortmichael.com/

• Social: LinkedIn, Facebook, Instagram, YouTube, X, Threads, TikTok

• Email: Michael@MassTortMichael.com

• Phone: 908-548-5378

Copyright

• Copyright © MassTortMichael. Please share this evaluation with attribution to help more firms make sound decisions.

Citations

• AHA News – https://www.aha.org/news/headline/2016-01-15-olympus-recalls-duodenoscope-model-safety-modification

• FDA Recall Z-2807-2015 (TJF‑Q180V; 2015 corrective actions; 6,109 units; labeling design cause) – https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=135241

• FDA Recall Z-0379-2022 (TJF‑Q180V; 2021 corrective action; 14,447 units; adhesive deterioration risk; transition guidance) – https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=190170

• Loeb & Loeb – Olympus Pays $85M for Failure to File Adverse‑Event Reports – https://www.loeb.com/en/insights/publications/2019/01/olympus-pays-85m

• Gastroenterology & Endoscopy News – Olympus Recalling Duodenoscopes to Reduce Infection Risk – https://www.gastroendonews.com/PRN/Article/01-16/Olympus-Recalling-Duodenoscopes-to-Reduce-Infection-Risk/34978

• JDSupra (Polsinelli) – Olympus to Pay $632.2 Million to Resolve Allegations of Kickbacks (context on financial capacity, paywalled in part) – https://www.jdsupra.com/legalnews/olympus-to-pay-632-2-million-to-resolve-83714

Future items to verify next

• Current JPML docket status for any Olympus duodenoscope/endoscope MDL.

• Any public bellwether verdicts or published global settlements post‑2019.

• Recent FDA 522 study outcomes or surveillance summaries specific to Olympus duodenoscopes.